Drug intelligence / Profile preview

IDN-1114

Development stage: Preclinical
Lead developer: Idun
Modality: Small Molecules

Overview

**IDN-1114** is a **caspase-1 inhibitor** developed by Idun Pharmaceuticals, a small molecule in preclinical development at the time of Pfizer's acquisition of Idun in 2005. Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a key enzyme in the inflammatory response, cleaving pro-IL-1β into its active form and activating the inflammasome pathway. IDN-1114 was intended for the treatment of **inflammatory diseases**, leveraging inhibition of caspase-1 to reduce inflammation. Following Pfizer's acquisition, its development status is unclear, with no evidence of advancement to clinical trials.[1]

Targets

CASP1 (Caspase-1)

Beyond the preview

Go deeper on IDN-1114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDN-1114.

Explore the full profile